Cellectis (CLLS) Liabilities and Shareholders Equity (2013 - 2026)

Cellectis' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $289.2 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 20.57% year-over-year to $289.2 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 15.46% decrease from a year earlier, with the FY2025 full-year figure at $324.7 million, down 15.34% from the prior year.
• Liabilities and Shareholders Equity eased to $289.2 million in Q1 2026 per CLLS's latest filing, from $324.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $407.1 million in Q2 2024 and bottomed at $209.7 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $334.3 million (2023), against an average of $320.5 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 32.29% in 2022 and jumped 88.78% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $261.2 million in 2022, then advanced by 27.97% to $334.3 million in 2023, then advanced by 14.74% to $383.5 million in 2024, then retreated by 15.34% to $324.7 million in 2025, then dropped by 10.94% to $289.2 million in 2026.
• Per Business Quant, the three latest CLLS Liabilities and Shareholders Equity figures stand at $289.2 million (Q1 2026), $324.7 million (Q4 2025), and $343.0 million (Q3 2025).